Velaglucerase alfa

Velaglucerase alfa, sold under the brand name Vpriv, is a medication used for the treatment of Gaucher disease Type 1.[1] It is a hydrolytic lysosomal glucocerebroside-specific enzyme, which is a recombinant form of glucocerebrosidase. It has an identical amino acid sequence to the naturally occurring enzyme.[2] It is manufactured by Shire plc.

Velaglucerase alfa
Clinical data
Trade namesVpriv
AHFS/Drugs.comMonograph
License data
Routes of
administration		Intravenous
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • US: ℞-only[1]
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
BioavailabilityN/A
Elimination half-lifePlasma: 5–12 minutes (absorbed by macrophages)
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC2532H3850N672O711S16
Molar mass55593.61 g·mol−1
 ☒NcheckY (what is this?)  (verify)

The most common side effects include abdominal (belly) pain, headache, dizziness, bone pain, arthralgia (joint pain), back pain, infusion-related reactions, asthenia (weakness) or fatigue (tiredness), and pyrexia (fever) or increased body temperature.[3]

Velaglucerase alfa was approved for medical use in the United States in February 2010,[4][5] and in the European Union in August 2010.[3]

Medical uses

Velaglucerase alfa is indicated for long-term enzyme-replacement therapy (ERT) in people with type-1 Gaucher disease.[3][1]

References
  1. "Vpriv- velaglucerase alfa injection, powder, lyophilized, for solution". DailyMed. 18 June 2020. Archived from the original on 24 March 2021. Retrieved 13 August 2020.
  2. Burrow TA, Grabowski GA (February 2011). "Velaglucerase alfa in the treatment of Gaucher disease type 1". Clinical Investigation. 1 (2): 285–293. doi:10.4155/cli.10.21. PMC 3172711. PMID 21927713.
  3. "Vpriv EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 29 October 2020. Retrieved 13 August 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  4. "Shire Announces FDA Approval Of Vpriv (velaglucerase Alfa For Injection) For The Treatment Of Type 1 Gaucher Disease". Medical News Today. 27 February 2010. Archived from the original on 13 June 2011. Retrieved 6 March 2010.
  5. "Drug Approval Package: Vpriv (Velaglucerase alfa) NDA #022575". U.S. Food and Drug Administration (FDA). 24 February 2010. Archived from the original on 3 April 2021. Retrieved 17 February 2023.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.